PolyNovo Showcases Revolutionary NovoSorb® BTM Synthetic Wound Matrix Technology at MEDICA 2022 -- MEDICA - World Forum for Medicine

31.10.2022

ABHI Association of British HealthTech Industries Ltd.

PolyNovo Showcases Revolutionary NovoSorb® BTM Synthetic Wound Matrix Technology at MEDICA 2022

PolyNovo UK Ltd – a UK medical devices company specialising in the development of surgical solutions using the patented polymer technology NovoSorb® – will be joining the ABHI UK Pavilion at MEDICA 2022 (14 – 17 November 2021) to showcase their cutting-edge NovoSorb BTM (Biodegradable Temporising Matrix) technology.

The patented NovoSorb® polymer technology was developed to fulfil the need for a synthetic biodegradable product that could be safely used in medical devices. NovoSorb polymers have advantageous properties such as biocompatibility and design flexibility. These properties underpin novel medical devices designed to support tissue repair, before they biodegrade in situ into biocompatible by-products via established pathways. NovoSorb BTM (Biodegradable Temporizing Matrix) is the first product commercialised by PolyNovo.

Today NovoSorb BTM is available for use in many countries throughout the world. The device was granted CE mark approval for sale throughout UK/Ireland and the European Union at the end of 2019.

The company is now looking forward to expanding its footprint across the Europe and we will be launching a new smaller size of the device, which is indicated for diabetic foot ulcers and venous leg ulcers, at this year’s MEDICA.

PolyNovo’s CEO, Swami Raote, said: “We are delighted to be joining the ABHI at this year’s MEDICA to showcase our pioneering BTM technology, designed to help surgeons treat traumatic wounds. Given that BTM is comprised of synthetic material it does not contain any food for bacteria and has shown to be robust and retain product integrity in the presence of infection. We look forward to connecting with new partners and distributors at this year’s show to extend its benefits to more patients across Europe and worldwide. Our vision is always to support improved patient care using the power of our disruptive NovoSorb technology in the treatment of complex wounds.”

When trauma to the skin occurs, large portions of the surface of the skin (epidermis) and its deeper layers (dermis) are destroyed.

BTM is used to treat complex wounds and burns where there has been a significant loss of tissue. It was invented and developed by PolyNovo using polymer technology originating from CSIRO (Commonwealth Science Industry Research Organization). BTM can be utilised for full thickness and deep dermal wounds including traumatic injuries, burns, necrotising soft tissue infections and chronic wounds.

The technology enables the generation of a vascularised neodermis which provides a more robust foundation for wound reconstruction than grafting alone. The device is also designed to limit wound scarring and contracture, providing an alternative option to lengthy, complex free-flap surgery. In addition, it is uniquely comprised of synthetic material, thus it does not contain any food for bacteria and has shown to be robust in the presence of infection.

MEDICA is taking place from 14 – 17 November 2022 and throughout the show, PolyNovo UK Ltd will be located on the ABHI UK Pavilion - Hall 16 Stand H48. For more information. visit http://www.polynovo.com.

Exhibitor Data Sheet